Month: September 2026

• First and only FDA-approved treatment of peripheral thyrotoxicosis in adults and pediatric patients with monocarboxylate transporter 8 (MCT8) deficiency in the United States
• Egetis launches Egetis RareLink™, the EMCITATE patient support program, in partnership with PANTHERx® Rare
• FDA granted Egetis a Rare Pediatric Disease Priority Review Voucher (PRV) in connection with the approval
• Egetis to host a conference call and webcast for analysts and investors on Tuesday September 29 at 8:00 am CEST (2:00 am EDT)

STOCKHOLM, SWEDEN, Sept. 28 2026. (GLOBE NEWSWIRE) – Egetis Therapeutics AB (publ) (“Egetis” or the “Company”) (Nasdaq Stockholm: EGTX) today announced that the U.S. Food and Drug Administration (FDA) has approved EMCITATE® (tiratricol), a thyroid hormone receptor agonist, for the treatment of peripheral thyrotoxicosis in adults and pediatric patients with monocarboxylate transporter 8 (MCT8) deficiency (Allan–Herndon–Dudley syndrome). EMCITATE is not recommended for the treatment of primary hypothyroidism. EMCITATE is the first FDA-approved treatment option for patients with MCT8 deficiency in the United States.

MCT8 deficiency is a rare, devastating, life-limiting, X-linked disorder caused by pathogenic mutations in the SLC16A2 gene. These mutations impair the function of MCT8, a critical cell-surface thyroid-hormone transporter responsible for thyroid hormone transport in specific cells, including in the brain. As a result, patients experience disrupted thyroid hormone signaling, characterized by insufficient thyroid hormone activity in the central nervous system and excessive exposure to the active thyroid hormone triiodothyronine (T3) in peripheral tissues. This leads to a complex disorder characterized by severe neurodevelopmental impairment and persistent peripheral thyrotoxicosis. Patients with MCT8 deficiency have a reported median life expectancy of approximately 35 years. For further details, please see ‘About MCT8 deficiency’ below.

The FDA approval of EMCITATE was supported by a comprehensive clinical development program evaluating EMCITATE in patients with MCT8 deficiency, including ReTRIACt, Triac Trial I, Triac Trial II, Erasmus Medical Center (EMC) Cohort Study, EMC Survival Study and the U.S. Expanded Access Program.  

“Today marks a turning point for patients living with MCT8 deficiency and their caregivers, who have waited long for an approved treatment in the United States. Our immediate focus is ensuring that eligible patients can access EMCITATE as quickly as possible,” said Nicklas Westerholm, Chief Executive Officer of Egetis Therapeutics. “We are deeply grateful to the patients, caregivers, investigators, clinicians, and advocacy organizations whose partnership and determination made this achievement possible as well as all Egetis employees and collaborators for their dedicated and hard work. Today also marks a defining milestone for Egetis as we take steps forward in developing medicines that address serious unmet medical needs for patients with rare diseases.”

 “Through my experience caring for patients with MCT8 deficiency, I have seen firsthand the profound impact this complex and life-limiting disorder can have on patients and their families. Early diagnosis is critical so that patients can be appropriately evaluated, connected with specialists and receive coordinated multidisciplinary care. The FDA approval of EMCITATE provides physicians in the United States with the first approved treatment option for patients and represents an important advance for the MCT8 deficiency community,” said Andrew J. Bauer, M.D., a pediatric endocrinologist and expert in thyroid hormone disorders and Principal Investigator in ReTRIACt trial and Triac Trial II, evaluating EMCITATE in MCT8 deficiency.

“The FDA approval of EMCITATE is a historic milestone for the MCT8 deficiency community and an important step toward ensuring patients have access to a treatment. We are grateful to Egetis and to the researchers, clinicians, patients, families, and advocates whose dedication helped bring this treatment to patients. This approval is a testament to what is possible when a community comes together with a shared commitment to advancing care. We look forward to continuing to advocate for patients and supporting efforts to expand awareness, access and treatment options for the worldwide MCT8 community.” said the MCT8-AHDS Foundation.

Launch of Egetis RareLink™: EMCITATE® comprehensive patient support program

Egetis is committed to helping eligible patients gain timely access to EMCITATE. The Company expects EMCITATE to be commercially available in the United States in eight to ten weeks post approval. Through Egetis RareLink, its dedicated patient support program, Egetis has established the access infrastructure—including specialty distribution and dedicated support resources—to help ensure a seamless experience for patients, caregivers, and healthcare professionals from day one. As part of its U.S. commercialization strategy, Egetis has partnered with PANTHERx® Rare to support medication access, education, care coordination and ongoing treatment services. For more information about Egetis RareLink, call 1-844-4EGETIS (1-844-434-3847).

Priority review voucher granted

In connection with the approval of EMCITATE, the FDA granted Egetis a Rare Pediatric Disease Priority Review Voucher (PRV).  The Company currently expects to explore monetization of the PRV, which could potentially occur in the fourth quarter of 2026, subject to market conditions.

Conference call and webcast information

Egetis will host a conference call and webcast for analysts and investors to discuss the FDA approval of EMCITATE beginning at 8:00 am CEST (2:00 am EDT) on Tuesday, September 29, 2026.

Webcast link: https://live.events.inderes.com/fda-approval-sep-2026  

Teleconference link: https://events.inderes.com/live/fda-approval-sep-2026/dial-in   

After registration to the teleconference you will be provided phone numbers and a conference ID to access the call. You can ask questions verbally via the teleconference. A replay of the webcast can be accessed via the webcast link above.

About MCT8 deficiency

Monocarboxylate transporter 8 (MCT8) deficiency, also known as Allan–Herndon–Dudley syndrome (AHDS), is a rare, devastating, life-limiting, X-linked disorder caused by pathogenic mutations in the SLC16A2 gene. These mutations impair the function of MCT8, a critical cell-surface thyroid hormone transporter responsible for thyroid hormone transport in specific cells, including in the brain. As a result, patients experience disrupted thyroid hormone signaling, characterized by insufficient thyroid hormone activity in the central nervous system and excessive exposure to the active thyroid hormone triiodothyronine (T3) in peripheral tissues. This leads to a complex disorder characterized by severe neurodevelopmental impairment and persistent peripheral thyrotoxicosis.

The elevated T3 concentrations in peripheral tissues can result in a chronic hypermetabolic state affecting multiple organs, including the heart, muscles, liver, and kidneys. Clinical manifestations may include failure to thrive, cardiovascular strain, muscle wasting, metabolic imbalance, and increased susceptibility to infections. These systemic consequences of persistent thyrotoxicosis are believed to contribute significantly to the increased morbidity and premature mortality associated with the disorder. Patients with MCT8 deficiency have a reported median life expectancy of approximately 35 years.

For more information about MCT8 deficiency, please visit MCT8deficiency.com or LifewithMCT8deficiency.com

INDICATION AND USAGE

EMCITATE is a thyroid hormone receptor agonist indicated for the treatment of peripheral thyrotoxicosis in adults and pediatric patients with monocarboxylate transporter 8 (MCT8) deficiency (Allan–Herndon–Dudley syndrome).

Limitation of use: EMCITATE is not recommended for the treatment of primary hypothyroidism.

IMPORTANT SAFETY INFORMATION

BOXED WARNING
NOT FOR TREATMENT OF OBESITY OR FOR WEIGHT LOSS

CONTRAINDICATIONS
Primary hyperthyroidism

WARNINGS AND PRECAUTIONS
Thyrotoxicosis: Signs and symptoms of thyrotoxicosis (e.g., increased heart rate, elevated blood pressure, diarrhea, hyperhidrosis, irritability, insomnia, nightmares) have occurred with EMCITATE during treatment initiation and dose titration. Monitor and adjust the EMCITATE dose as indicated.
Laboratory Test Interference for T3 Measurement: Tiratricol can cross-react with immunoassays for T3 leading to unreliable T3 results and cause an overestimation of T3.

ADVERSE REACTIONS
Most common adverse reactions (≥ 5%): diarrhea, vomiting, rash, and hyperhidrosis.

To report SUSPECTED ADVERSE REACTIONS, contact Egetis Therapeutics US Inc. at 1-844-4EGETIS (1-844-434-3847) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see full Prescribing Information here: https://www.egetis.com/wp-content/uploads/emcitate-full-prescribing-information.pdf

About Egetis Therapeutics

Egetis Therapeutics is a commercial-stage pharmaceutical company focused on developing and delivering innovative therapies for patients with rare diseases with significant unmet medical need. Combining scientific and clinical expertise with integrated late-stage development, regulatory and commercial capabilities and manufacturing expertise, Egetis is committed to delivering treatments and dedicated support to underserved patient communities. The Company’s lead product, EMCITATE® (tiratricol), is the first and only approved treatment for MCT8 deficiency, a rare and life-shortening genetic disorder, with marketing authorizations in the European Union and now in the United States. Headquartered in Stockholm, Sweden, with operations in the U.S. and Europe, Egetis is building a sustainable global rare disease company.

For more information, visit egetis.com and follow the Company on LinkedIn.

About PANTHERx Rare 

PANTHERx Rare makes rare disease care more hyper-personalized and less overwhelming by focusing relentlessly on each patient and each therapy. PANTHERx experts develop deep personal relationships with patients, prescribers, and pharmaceutical partners, serving as trusted advocates to ensure seamless collaboration and exceptional care. Since its founding in a garage in Pittsburgh, PA in 2011, PANTHERx has grown into the largest independent rare pharmacy in the U.S., leveraging established-company resources while maintaining small-company responsiveness, innovation, and attention to detail.

PANTHERx is licensed in all 50 states and U.S. territories and was the first national pharmacy to achieve dual accreditations in rare disease from the Accreditation Commission for Health Care (ACHC) and Utilization Review Accreditation Commission (URAC). PANTHERx is also the nine-time winner of the prestigious MMIT Patient Choice Award for patient satisfaction, including the 2026 honor.

For more information, please email TheRareSP@pantherxrare.com or visit www.pantherxrare.com

Contacts

Nicklas Westerholm, CEO
nicklas.westerholm@egetis.com
+46 (0) 733 542 062

Karl Hård, Head of Investor Relations, Communications & Business Development
karl.hard@egetis.com
+46 (0) 733 011 944

This information is information that Egetis Therapeutics is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 11:46 pm CEST on September 28, 2026.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of applicable securities laws, including statements regarding the commercialization and availability of EMCITATE® (tiratricol) in the United States, the timing and outcome of potential monetization of the Rare Pediatric Disease Priority Review Voucher, the expected capabilities of the Company’s patient access and distribution infrastructure, the anticipated benefits of EMCITATE for patients with MCT8 deficiency, and the Company’s broader strategic plans for the development and commercialization of therapies for rare diseases. Forward-looking statements can generally be identified by words such as “expects,” “anticipates,” “intends,” “believes,” “estimates,” “plans,” “will,” “may,” “could,” “potential,” or similar expressions, although not all forward-looking statements contain these words.
These statements are based on the Company’s current expectations, assumptions, and assessments as of the date of this press release and are subject to risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed or implied. Such factors include, but are not limited to: risks related to the commercial launch and market acceptance of EMCITATE in the United States; the ability to establish and maintain adequate commercial infrastructure, including distribution, patient support, and reimbursement arrangements; the timing and terms of any monetization of the Priority Review Voucher, which is subject to market conditions and the availability of interested purchasers; potential post-marketing requirements or restrictions imposed by the FDA; the ability to maintain regulatory approvals in the United States and the European Union; competition from existing or future therapies; the Company’s ability to secure adequate funding for its operations and commercial activities; and general economic, market, and business conditions.
For a further description of risks and uncertainties that could affect the Company’s business and results, reference is made to the Company’s most recent annual report and other filings with relevant regulatory authorities available at www.egetis.com. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by applicable law or regulation.

NEW YORK, September 28, 2026 — 21shares, one of the world’s largest issuers of cryptocurrency exchange traded funds (ETFs), today announced the following shareholder distributions for the 21shares Ethereum Staking ETF (TETH), 21shares Solana Staking ETF (TSOL), 21shares Hyperliquid Staking ETF (THYP), 21shares Sui Staking ETF (TSUI), and 21shares Polkadot Staking ETF (TDOT). Distributions consist of staking rewards earned from staked ETH, SOL, HYPE, SUI, and DOT tokens by each fund, respectively.

Ticker	Name	Distribution	Ex/Record date	Payable date
TETH	21shares Ethereum Staking ETF	$0.031602	9/29/2026	9/30/2026
TSOL	21shares Solana Staking ETF	$0.076590	9/29/2026	9/30/2026
THYP	21shares Hyperliquid Staking ETF	$0.191360	9/29/2026	9/30/2026
TSUI	21shares Sui Staking ETF	$0.052939	9/29/2026	9/30/2026
TDOT	21shares Polkadot Staking ETF	$0.045029	9/29/2026	9/30/2026

About 21shares

21shares is one of the world’s leading cryptocurrency exchange traded product (ETP) providers and offers one of the largest suites of crypto ETPs in the market. The company was founded to make cryptocurrency more accessible to investors, and to bridge the gap between traditional finance and decentralized finance. 21shares listed the world’s first physically-backed crypto ETP in 2018, building a seven-year track record of creating crypto ETPs that are listed on some of the biggest, most liquid securities exchanges globally. Backed by a specialized research team, proprietary technology, and deep capital markets expertise, 21shares delivers innovative, simple and cost-efficient investment solutions.

21shares is a subsidiary of FalconX, one of the world’s largest digital asset prime brokers. 21shares maintains independent operations from FalconX while strategically leveraging the resources and reach of FalconX to accelerate its mission and unlock new growth. For more information, please visit www.21shares.com.

Media Contact
Audrey Belloff: audrey.belloff@21Shares.com
Alethea Jadick: ajadick@sloanepr.com

Important Information

The 21shares Ethereum Staking ETF (TETH), 21shares Solana Staking ETF (TSOL), 21shares Sui Staking ETF (TSUI), 21shares Polkadot Staking ETF (TDOT), and 21shares Hyperliquid Staking ETF (THYP) (referred to collectively as the “Trusts”), are not registered under the Investment Company Act of 1940 (the “40 Act”) and therefore are not subject to the same regulations and protections as 40 Act registered ETFs and mutual funds. Investing involves significant risk, including possible loss of principal. An investment in the Trusts is subject to a high degree of risk and heightened volatility and not suitable for all investors. The Trusts are not suitable for an investor who cannot afford the loss of the entire investment. An investment in the Trusts is not a direct investment in ETH, SOL, SUI, DOT, or HYPE.

Investing involves significant risk, including the possible loss of principal. There is no assurance that the Trusts will generate a profit for investors.

Ethereum, Solana, Sui, Polkadot, and Hyperliquid are relatively new asset classes, and the market for these assets is subject to rapid changes and uncertainty. Ethereum, Solana, Sui, Polkadot, and Hyperliquid are largely unregulated and these investments may be more susceptible to fraud and manipulation than more regulated investments.

Must be preceded or accompanied by the prospectuses for TETH (here), TSOL (here), TSUI (here), TDOT (here), and THYP (here).

The Trusts participate in staking a portion of their holdings in order to generate additional rewards. Staking involves committing assets to support the operations of a blockchain and, in return, may provide rewards to the relevant Trusts. While staking can potentially enhance returns, it also introduces additional risks, including operational, technological, regulatory, and counterparty risks. Staking Ethereum, Solana, Polkadot, Sui, or Hyperliquid introduces several risks, including the possibility of losing staked Ethereum, Solana, Polkadot, Sui, or Hyperliquid through penalties, slashing, or inactivity leaks if validators behave poorly, go offline, or violate protocol rules. Staked Ethereum, Solana, Polkadot, Sui, and Hyperliquid can also be locked for long and unpredictable periods due to activation and exit queues, creating liquidity constraints and making it harder to meet redemptions. Because staking depends heavily on third-party providers, operational failures, outages, cybersecurity breaches, or mismanagement by these providers could lead to lost assets or reduced rewards. Rewards themselves are uncertain and can fluctuate based on network conditions, validator performance, governance changes, commission rates, and downtime. Additionally, staking may create conflicts of interest if operators are incentivized to stake more Ethereum, Solana, Polkadot, Sui, or Hyperliquid than is prudent, increasing liquidity risk.

Ethereum, Solana, Sui, Polkadot, and Hyperliquid are subject to unique and substantial risks, including significant price volatility, lack of liquidity, and theft. The value of an investment in any of the Trusts could decline significantly and without warning, including to zero. Ethereum, Solana, Sui, Polkadot, and Hyperliquid are subject to rapid price swings, including as a result of actions and statements by influencers and the media, changes in supply and demand, and other factors. There is no assurance that Ethereum, Solana, Sui, Polkadot, or Hyperliquid will maintain their value over the long-term.

Failure by a Trust’s Custodian to exercise due care in the safekeeping of the Trust’s underlying digital assets, as applicable, could result in a loss to the Trust. Shareholders cannot be assured that a Custodian will maintain adequate insurance with respect to the digital assets held by the custodian on behalf of the Trust.

The Trusts are not actively managed and will not take any actions to take advantage, or mitigate the impacts, of volatility in the price of their underlying digital assets, as applicable. An investment in a Trust is not a direct investment in Ethereum, Solana, Sui, Polkadot, or Hyperliquid. Investors will also forgo certain rights conferred by owning these digital assets directly. Shares of a Trust are generally bought and sold at market price (not NAV) and are not individually redeemed from the Trust. Only Authorized Participants may trade directly with a Trust and only in large blocks of Shares called “creation units.” Your brokerage commissions will reduce returns.

Shares in the Trusts are not FDIC insured, may lose value, and have no bank guarantee.

The Marketing Agent for each Trust is Foreside Global Services, LLC. 21shares US LLC is the Sponsor to each Trust. 21shares is not affiliated with Foreside Global Services, LLC. FalconX is not affiliated with Foreside Global Services, LLC.

© 2026 21shares US LLC. No part of this material may be reproduced in any form, or referred to in any other publication, without written permission.

###

TORONTO, Sept. 28, 2026 (GLOBE NEWSWIRE) — Aberdeen International Inc. – (“Aberdeen” or the “Company”) (TSX: AAB) reports, in accordance with the policies of the Toronto Stock Exchange, that the nominees listed in the management information circular dated August 28, 2026, for the 2026 annual general and special meeting of shareholders of Aberdeen held on September 28, 2026, (the “Meeting”) were elected as directors of the Company. Aberdeen management would like to thank shareholders for their participation and continuing support.

Detailed results of the vote for the election of directors held at the Meeting are set out below. A total of 50,050,225 common shares were voted in connection with the Meeting, representing approximately 31.146% of the issued and outstanding common shares of the Company.

Election of Directors

The shareholders approved the election as directors of the persons listed below, based on the following vote:

Nominee	Percentage of Votes For	Percentage of Votes Withheld
Fred Leigh	98.817%	1.183%
Gregory Biniowsky	67.441%	32.559%
Dev Shetty	67.249%	32.751%

Shareholders at the Meeting also (i) approved the appointment of McGovern Hurley LLP as the Company’s auditors, and (ii) set the number of directors at three (3).

The special resolution respecting a proposed consolidation of the Company’s common shares on the basis of up to 10 for one was not approved at the Meeting and was therefore revoked due to insufficient shareholder support.

ABOUT ABERDEEN INTERNATIONAL INC.

Aberdeen is a global resource investment company and merchant bank focused on small capitalization companies in the rare metals and renewable energy sectors.

For further information, please contact:

Dev Shetty
Executive Chairman and Chief Executive Officer
Aberdeen International Inc.
Dev.Shetty@aberdeen.green

VANCOUVER, British Columbia, Sept. 28, 2026 (GLOBE NEWSWIRE) — Giga Metals Corp. (TSX-V: GIGA; OTCQB: GIGGF; FSE: BRR2) (“Giga Metals” or the “Company”) today announced that effective September 28, 2026, and subject to the provisions of the Turnagain Joint Venture agreement dated August 15, 2022, Mitsubishi Corp (“Mitsubishi”) has elected to exercise its Put Right (“the Put”) and has agreed to sell its approximate 15% in the Turnagain Joint Venture back to Giga for nominal consideration. The Put and associated repurchase of the Joint Venture interest is anticipated to close on or around October 12, 2026.

“We would like to express our sincere appreciation for the opportunity to partner with Giga Metals on the Turnagain project since 2022” said Kota Ikenishi, General Manager of the Battery Minerals Department, Mitsubishi Corporation. “This decision is not a reflection of Turnagain, nor of the dedication, commitment, and hard work demonstrated by the Giga team. Rather, it is the result of Mitsubishi’s broader portfolio review and assessment of the North American nickel and EV markets since investment.”

“We want to thank Mitsubishi for its investment in the Turnagain project,” said Scott Lendrum, CEO of Giga Metals Corp. “Together, we completed a robust Pre-Feasibility study of our nickel/cobalt deposit in 2023. Since then, due to continued uncertainty in the nickel market, we have turned our attention to the copper exploration potential in the 80% of the Turnagain ultramafic system that remains unexplored or underexplored. A multi-phase exploration program is currently underway, guided by Dr. Stephen Beresford, with an emphasis on known copper mineralization and the significant potential of the Attic Zone.”

About Giga Metals Corporation
Giga Metals Corporation’s core asset is the Turnagain Project located in northern British Columbia, which contains one of the few significant undeveloped sulfide nickel and cobalt resources in the world. The Pre-Feasibility Study was released in October 2023. The Turnagain ultramafic complex is also prospective for copper, platinum and palladium mineralization in the Attic Zone, an area adjacent to the known nickel resource.

Qualified Person
Technical information herein has been reviewed and approved by Greg Ross, P.Geo. Mr. Ross is the Project Manager for Giga Metals and is a Qualified Person under NI 43-101.

Forward-looking Statements
Certain statements in this news release are forward-looking statements, which reflect the expectations of the Company. Forward-looking statements consist of statements that are not purely historical, including any statements regarding beliefs, plans, expectations or intentions regarding the future. Such statements include, but are not limited to, completion of the Private Placement and any additional funding for the Turnagain Project. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. These forward-looking statements reflect management’s current views and are based on certain expectations, estimates and assumptions which may prove to be incorrect. A number of risks and uncertainties could cause our actual results to differ materially from those expressed or implied by the forward-looking statements, including: the conditions to closing of the Private Placement may be not be satisfied; the Company may not be able to locate suitable investors for the Private Placement and the terms for any additional funding of the Turnagain Project may not be finalized. These forward-looking statements are made as of the date of this news release and, except as required by applicable securities laws, the Company assumes no obligation to update these forward-looking statements, or to update the reasons why actual results differed from those projected in the forward-looking statements.

On behalf of the Board of Directors of Giga Metals Corporation

“Scott Lendrum”

SCOTT LENDRUM, 
CEO & Director

Contact Information
Office Phone: +1 (604) 681-2300
Investor Inquiries: info@gigametals.com
Company Website: www.gigametals.com

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Suite 604 – 700 West Pender St., Vancouver, BC, Canada V6C 1G8